NYSE:BIO.B - Get Free Report ) shares hit a new 52-week low on Tuesday . The company traded as low as $268.80 and last traded at $268.95, with a volume of 135 shares traded. The stock had previously closed at $279.91.
Get Bio-Rad Laboratories alerts:
Sign Up
Bio-Rad Laboratories Stock Performance The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of -13.03 and a beta of 0.66. The stock's fifty day moving average is $326.03 and its two-hundred day moving average is $316.86. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.
Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report ) last issued its earnings results on Thursday, February 15th. The company reported $3.10 earnings per share for the quarter. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The business had revenue of $681.18 million for the quarter.
About Bio-Rad Laboratories (
Get Free Report )
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
See Also This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
